Literature DB >> 32766992

Adoption of Opioid-Sparing and Non-Opioid Regimens After Breast Surgery in a Large, Integrated Health Care Delivery System.

Avani R Patel1, Brooke Vuong2, Gillian E Kuehner3, Patience Odele4, Garner Low5, Alison Savitz6, Veronica Shim7, Margaret Mentakis2, Elizabeth Linehan8, Sharon B Chang9.   

Abstract

BACKGROUND: Postoperative prescriptions have contributed to the opioid epidemic. In response, a large, integrated health care delivery system implemented initiatives to reduce outpatient opioid prescriptions. We evaluated the impact of these interventions on opioid-prescribing practices after breast surgery.
METHODS: We examined postoperative prescribing practices before and after the 2016-2018 intervention period. Primary endpoints were the use of non-opioid regimens (NORs) and morphine milligram equivalents (MMEs) prescribed for postoperative pain management, while secondary endpoints were emergency department (ED) visits and readmissions within 7 days of surgery.
RESULTS: In a survey of breast surgeons, 23% reported using NORs in 2017 versus 79% in 2019 (p < 0.001). Comparing 1917 breast operations from 2016 with 2166 operations from 2019, NORs increased from 9% in 2016 to 39% in 2019 (p < 0.001). Average discharge MMEs per operation decreased from 190 in 2016 to 106 in 2019 (p < 0.001). NOR failure (defined as an additional opioid prescription within 2 weeks of surgery) was < 1%. Significantly fewer postoperative ED visits occurred in the NOR group (1.9% NOR vs. 3.4% opioid regimen [OR]; p < 0.001). The 7-day readmission rates for NOR and OR patients were similar (0.49% NOR vs. 0.32% OR; p = 0.45).
CONCLUSION: Between 2016 and 2019, breast surgeons in a large, integrated health care delivery system adopted NORs for nearly 40% of breast operations, and prescribed significantly fewer MMEs, with no increases in ED visits or readmissions for NOR patients. This suggests that initiatives to decrease opioid prescribing were successful and that a NOR for pain management after breast surgery is feasible.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32766992     DOI: 10.1245/s10434-020-08897-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system.

Authors:  Annie Tang; Elad Neeman; Brooke Vuong; Vignesh A Arasu; Raymond Liu; Gillian E Kuehner; Alison C Savitz; Liisa L Lyon; Prachi Anshu; Samantha A Seaward; Milan D Patel; Laurel A Habel; Lawrence H Kushi; Margaret Mentakis; Eva S Thomas; Tatjana Kolevska; Sharon B Chang
Journal:  Breast Cancer Res Treat       Date:  2022-01-06       Impact factor: 4.624

2.  Implementation of Intraoperative Ultrasound Localization for Breast-Conserving Surgery in a Large, Integrated Health Care System is Feasible and Effective.

Authors:  Jeffery M Chakedis; Annie Tang; Gillian E Kuehner; Brooke Vuong; Liisa L Lyon; Lucinda A Romero; Benjamin M Raber; Melinda M Mortenson; Veronica C Shim; Nicole M Datrice-Hill; Jennifer R McEvoy; Vignesh A Arasu; Dorota J Wisner; Sharon B Chang
Journal:  Ann Surg Oncol       Date:  2021-08-26       Impact factor: 5.344

3.  The Virtual Scientific Sessions from the American Society of Breast Surgeons During the COVID-19 Pandemic.

Authors:  Henry M Kuerer; Sarah L Blair
Journal:  Ann Surg Oncol       Date:  2020-08-18       Impact factor: 5.344

4.  Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia.

Authors:  Kate R Pawloski; Regina Matar; Varadan Sevilimedu; Audree B Tadros; Laurie J Kirstein; Hiram S Cody; Kimberly J Van Zee; Monica Morrow; Tracy-Ann Moo
Journal:  Ann Surg Oncol       Date:  2021-07-10       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.